A research study titled, “Gout Therapeutics Market by Product
Type and Disease Condition - Global Industry Analysis and Forecast to 2025”
published by Crystal Market Research, states that the gout therapeutics market
is projected to be around $8 billion by 2025.
Gout is the
most common form of inflammatory arthritis worldwide. It is characterized by
pain, redness and tenderness in joints. Gout is crystal-deposition disease due
to over production of uric acid above saturation level leading to crystal
formation. The incidence of gout has been increasing rapidly worldwide with
every six individuals in 1,000 suffering from gout and its related
complications based on study conducted by US National Health and Nutrition
Examination Surveys (NHANES). Gout conditions are more prevalent in men between
ages of 40 to 50 whereas in women chances of developing gout infections
increases after onset of menopause. Hence, rising incidence of gout will demand
more advanced drugs for treating gout and its related conditions. Gout
therapeutic market is expected to witness significant growth due to rise in
elderly population, rise in obesity and approval of effective gout therapies.
Non-steroidal
anti-inflammatory drugs (NSAIDs) segment dominated the global market in 2016.
This can be attributed to number of factors such as low cost of NSAIDs, easy
availability, and ability to induce anti-inflammatory response faster than
other available drugs for gout attacks. Additionally, introduction of advanced
and new drugs (such as TMX 67, Krystexxa, and Zurampic) for gout treatment,
increase in adoption rate of gout drugs, and huge investments for drug
designing and development are set to further drive the demand for NSAIDS.
Corticosteroids segment is expected to witness slow growth due to reoccurrence
of gout attack after withdrawal of steroids/drugs. Urate lowering drugs segment
has seen tremendous growth in last few years due to their ability of producing
strong anti-inflammatory response by inhibiting xanthine oxidase.
Get Free Sample of this
Report@: http://www.crystalmarketresearch.com/report-sample/HC055
In 2016, the global market was dominated by North America.
This large share can be attributed to number of factors such as rise in
incidence of gout infections and high adoption of technologically advanced
products. European market is expected to grow at considerable CAGR during the
forecast period, due to increased number of drug approvals. For instance, in
February 2016, AstraZeneca’s product, Zurampic in combination of xanthine
oxidase inhibitor, was approved by European Union. Therefore, introduction of
urate-lowering agents in European market will drive the market growth.
Some of the
major companies are Merck& Co. Inc.; GlaxoSmithKline plc; Teijin Pharma
Ltd.; Regeneron Pharmaceuticals; Novartis AG; Savient Pharmaceuticals; Takeda
Pharmaceutical Company Ltd.; and AstraZeneca plc. Market is expected to grow
further by national and international collaborations and partnership for
developing safety profile in treating such conditions. For instance, in Dec 2015,
Horizon Pharma plc acquires Crealta Holdings LLC for developing and
commercialization of medicines such as KRYSTEXXA for treating refractory gout
disease.
Get complete access of the Report @ http://www.crystalmarketresearch.com/report/gout-therapeutics-market
Competitive
Insights
Numerous
multinational as well as local players dominate the global market. Major
players comprise GlaxoSmithKline plc; Merck& Co. Inc.; AstraZeneca plc;
Teijin Pharma Ltd.; Novartis AG; Takeda Pharmaceutical Company Ltd.; Savient
Pharmaceuticals; and Regeneron Pharmaceuticals. Development of new and
innovative products, collaborations and strategic acquisitions are some of the
strategies acquired by market players to have competitive advantage over their
rivals.
Market
Opportunities
Major
players in market are shifting their focus towards more serious gout cases in
order to meet unmet medical needs of drugs for effective treatments. NSAIDs and
Colchicines are expected to attract large investment due to their increasing
adoption and success rate in treating acute as well as chronic gout disease.
Many players have collaborated for research and development to develop more
efficient drug for the treatment of gout diseases. The market will be
dominated by urate lowering agents that has ability to prevent gout disease by
blocking genes responsible for gout disease. With FDA approval of Zurampic (in
2015) to reduce uric acid level in blood and other new drugs in clinical trials
will bring in huge opportunities for key players in the market.
Gout
therapeutic market is segmented as follows –
By
Product Type:
- Colchicines
- Corticosteroids
- NSAIDs
- Urate-lowering
Agents
By
Disease Condition:
- Acute
Gout
- Chronic
Gout
Inquiry
before Buying@ http://www.crystalmarketresearch.com/send-an-enquiry/HC055
About
Crystal Market Research
Crystal
Market Research is a U.S. based market research and business intelligence
company. Crystal offers one stop solution for market research, business intelligence,
and consulting services to help clients make more informed decisions. It
provides both syndicated as well as customized research studies for its
customers spread across the globe. The company offers market intelligence
reports across a broad range of industries including healthcare, chemicals
& materials, technology, automotive, and energy.
Contact Us:
304
South Jones Blvd, Suite 1896,
Las
Vegas NV 89107,
United
States
Toll Free:
+ 1-888-213-4282
Email:
sales@crystalmarketresearch.com
Website:
www.crystalmarketresearch.com
No comments:
Post a Comment